BeOne Medicines AG CEO John Oyler sold 109,713 American Depositary Shares for $34.6 million at a weighted average price of $315.28 per share under a pre-established Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains over 50.4 million ordinary shares through direct and indirect holdings, including 28.2 million shares held by Oyler Investment LLC and 9.5 million shares in a Roth IRA PENSCO trust account. Each American Depositary Share represents 13 ordinary shares, making the sold stake a fraction of a percent of his total position. The company reported first-quarter revenue of $1.5 billion, up 35%, with GAAP net income of $227.4 million, and raised full-year guidance to between $6.3 billion and $6.5 billion.
BeOne Medicines AGCEO sold $34.6M in stock under a pre-set plan, but retains vast majority; company raised guidance on strong Q1 results.
BeiGene Ltd.